Post-Deadline Reality Check: I’ve Submitted My IVDR Class C – Now What?

Submitted your IVDR Class C application? Learn what happens next, common causes of delays, review timelines, and why the September 2026 contract deadline is critical for maintaining EU market access.

Published 2nd June 2026

The IVDR Submission Deadline Has Passed — But the Real Work Is Just Beginning

The 26 May 2026 IVDR Class C submission deadline marked a major milestone for IVD manufacturers across Europe. Thousands of companies rushed to finalise technical documentation, Performance Evaluation Reports (PERs), Quality Management System updates, and Notified Body applications before the cut-off date.

Now, many manufacturers find themselves in a new phase of the IVDR journey: the waiting room.

Submitting your application does not guarantee uninterrupted EU market access. In reality, the months following submission are often where the most critical compliance risks emerge. Delayed responses, incomplete application notices, contract issues, and technical documentation deficiencies continue to prevent many Class C IVD manufacturers from progressing toward certification.

This article explains what happens after IVDR Class C submission, what timelines to realistically expect, and the key actions manufacturers must take now to avoid losing market access.

What Happens After an IVDR Class C Submission?

For many manufacturers, there is a misconception that once the application is submitted, the hard part is over.

Under the EU IVDR (Regulation (EU) 2017/746), the post-submission phase is often more demanding than the initial application process itself.

Most manufacturers will now enter one of several stages:

  • Administrative review
  • Completeness check
  • Technical documentation assessment
  • Performance evaluation review
  • QMS assessment
  • Corrective action cycles
  • Certification decision

The entire process can take anywhere from 12 to 18 months — and in some cases longer depending on:

  • Notified Body capacity
  • Device complexity
  • Documentation quality
  • Responsiveness to deficiencies
  • Number of devices in the application scope

Understanding the 12–18 Month IVDR Review Timeline

Why IVDR Reviews Take So Long

Unlike the previous IVDD framework, the IVDR requires significantly deeper scrutiny of:

  • Scientific validity
  • Analytical performance
  • Clinical performance
  • Risk management
  • PMS systems
  • Usability engineering
  • Stability evidence
  • Manufacturing controls

Notified Bodies are now conducting far more detailed technical reviews than ever before.

For Class C IVDs, this means manufacturers should prepare for:

  • Multiple rounds of questions
  • Requests for clarification
  • Additional evidence requests
  • CAPA requirements
  • Expanded technical assessments

Typical IVDR Review Stages After Submission

1. Administrative Completeness Review

This is usually the first step after submission.

The Notified Body checks whether:

  • Required forms are completed
  • Technical documentation is present
  • QMS certificates are included
  • Device lists are accurate
  • Application scope is clearly defined

At this stage, manufacturers commonly receive:

  • Requests for missing documents
  • Clarification requests
  • Incomplete Application notices

2. Technical Documentation Assessment

Once accepted administratively, the technical review begins.

This includes detailed evaluation of:

  • Performance Evaluation Reports (PERs)
  • Scientific validity evidence
  • Stability studies
  • Risk management files
  • IFUs and labelling
  • PMS documentation
  • PMPF plans
  • Software validation
  • Usability engineering

This phase can take many months depending on the number of products submitted.

3. Quality Management System (QMS) Review

Notified Bodies also assess whether the manufacturer’s ISO 13485 QMS adequately supports IVDR requirements.

Common focus areas include:

  • Supplier controls
  • PMS integration
  • Vigilance procedures
  • Change management
  • UDI implementation
  • Complaint handling
  • Clinical evidence maintenance

4. Non-Conformity and CAPA Cycles

Few IVDR applications pass without deficiencies.

Manufacturers should expect:

  • Major non-conformities
  • Minor non-conformities
  • Requests for additional evidence
  • CAPA implementation deadlines

Response times are critical. Delayed or incomplete responses can significantly extend timelines.

The Most Common Delay: “Incomplete Application” Notices

What Is an Incomplete Application Notice?

One of the most common reasons IVDR projects stall is because the application fails the initial completeness review.

An “Incomplete Application” notice means the Notified Body believes essential documentation or information is missing before formal review can begin.

This does not necessarily mean the submission has failed — but it can create major delays.

Common Reasons Manufacturers Receive Incomplete Application Notices

Typical causes include:

  • Missing Performance Evaluation documentation
  • Incorrect device classification rationale
  • Incomplete Annex II/III documentation
  • Poorly structured technical files
  • Missing PMS procedures
  • Inconsistent intended purpose statements
  • Missing software validation evidence
  • Inadequate risk management linkage
  • Unclear device grouping rationale

Many manufacturers underestimate the importance of:

  • Document traceability
  • Cross-referencing
  • Consistency across files
  • Structured submission formatting

How to Respond to an Incomplete Application Notice

If you receive an incomplete application notification:

  • Respond immediately
  • Clarify timelines with your Notified Body
  • Prioritise high-risk gaps first
  • Maintain documented communication trails
  • Ensure updated files are version controlled
  • Conduct internal peer reviews before resubmission

Fast and well-organised responses can prevent months of unnecessary delays.

The September 2026 Contract Deadline: The Critical Next Step

Why the Signed Contract Matters

One of the biggest misunderstandings in the IVDR transition is the belief that submission alone protects market access.

In reality, manufacturers must also ensure a formal written agreement with a Notified Body is signed by September 2026.

Without a signed agreement in place, many transitional provisions may no longer apply.

This could place continued EU market access at risk.

What Happens If You Miss the Contract Deadline?

Manufacturers without signed agreements may face:

  • Loss of transitional protection
  • Product withdrawal requirements
  • Distribution interruptions
  • Importer uncertainty
  • Increased regulatory scrutiny
  • Potential loss of CE marking continuity

Given current Notified Body capacity constraints, securing contractual arrangements early is essential.

Why Notified Body Capacity Remains a Major IVDR Risk

Even after the May 2026 deadline, the IVDR bottleneck is far from resolved.

Many Notified Bodies continue to experience:

  • Resource shortages
  • Long technical review queues
  • Delayed audit scheduling
  • Specialist reviewer shortages
  • Increasing application complexity

Manufacturers should expect prolonged timelines throughout 2026 and potentially into 2027.

Key Areas Manufacturers Should Focus on Right Now

1. Maintain Technical Documentation Readiness

Do not assume submitted files are “finished.”

Your team should continue updating:

  • PMS data
  • Vigilance records
  • PER literature reviews
  • Stability evidence
  • Risk management files

Many Notified Bodies request updated evidence during review.

2. Prepare for Deficiency Questions Early

Develop internal response procedures now.

This includes:

  • Assigning regulatory owners
  • Creating document tracking systems
  • Establishing response timelines
  • Coordinating SMEs
  • Preparing CAPA workflows

Rapid responses improve review efficiency.

3. Monitor Contract Status Carefully

Manufacturers should maintain direct visibility over:

  • Contract negotiations
  • Scope confirmations
  • Device lists
  • Review timelines
  • Audit scheduling

Delays in administrative processes can become regulatory risks.

4. Strengthen Post-Market Surveillance Systems

Notified Bodies are placing growing emphasis on:

  • Trend reporting
  • PMS plans
  • PMPF activities
  • Vigilance integration
  • Benefit-risk monitoring

Weak PMS systems remain a major source of IVDR non-conformities.

Frequently Asked Questions

No. Submission alone is not enough. Manufacturers must still progress through technical review and ensure signed Notified Body agreements are in place within required timelines.

 

Most reviews currently take approximately 12–18 months depending on:

  • Device complexity
  • Application quality
  • Reviewer availability
  • Number of deficiencies raised

 

Incomplete applications and poorly structured technical documentation remain the most common causes of delays.

 

Potentially yes, provided transitional requirements are met and contractual obligations with the Notified Body remain compliant.

Final Thoughts: Submission Was the Beginning — Not the Finish Line

For many IVD manufacturers, the May 2026 submission deadline felt like the end of a marathon.

In reality, it was only the beginning of the certification journey.

The next 12–18 months will determine whether manufacturers successfully achieve IVDR certification or face costly delays, market disruption, and increased regulatory risk.

Organisations that remain proactive — particularly around technical documentation quality, deficiency management, PMS systems, and contract readiness — will be best positioned to maintain uninterrupted EU market access.

Need Help Managing Your IVDR Submission?

At Patient Guard Ltd, we support IVD manufacturers throughout every stage of the IVDR transition process.

Our regulatory experts can help with:

  • IVDR technical documentation remediation
  • Performance Evaluation Reports (PERs)
  • Gap analyses
  • Deficiency response support
  • PMS and PMPF systems
  • Notified Body readiness
  • ISO 13485 integration
  • Risk management alignment
  • Regulatory strategy planning

If your organisation is currently navigating the post-submission review phase, our team can help reduce delays and strengthen your pathway to certification.

Contact Patient Guard Ltd Today for IVDR Support and Strategic Guidance

David Small BSc (Hons), MSc, MTOPRA

David Small BSc (Hons), MSc, MTOPRA

Reviewed by
David Small, BSc (Hons), MSc, MTOPRA
Founder & CEO |
20+ years in medical device regulatory affairs,  MDR/IVDR compliance and quality systems.

Patient Guards Recent Posts

Need Training?

Do you need training on Quality Management Systems or EU MDR/ EU IVDR? then check out our training courses.

Share this guide:

Most Popular

patient guard
Patient Guard

Sign up to our newsletter

Be the first to hear industry news and how Patient Guard can help you.

Get the latest updates on medical device regulation

Sign up to our newsletter and we’ll deliver news and insights straight to your inbox.
Patient Guard Regulatory Affairs and Quality Assurance

Get the Medical Device Technical Checklist

Thank you! The checklist is now ready to download.

checklist-tablet